Fig. 4. Activity of PGC–PTX NPs against cancer cells in vitro. (a) MSTO-211H, (b) A549, and (c) PANC-1 cells were treated with PGC–PTX NPs with varying PTX loadings in mol%, PTX-C/E, PTX–SA-C/E, or drug-free PGC–Bn NPs (given at equivalent PGC backbone concentrations to 34% PGC–PTX NPs). Cell viability was assessed after 5 days of treatment. All experiments were performed in triplicate, with data presented as mean ± standard deviation.
